Trial Profile
Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multicentre clinical phase 2, placebo controlled and double blind proof of concept study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Levosalbutamol (Primary)
- Indications Discoid lupus erythematosus; Systemic lupus erythematosus
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astion Pharma A/S
- 27 Jul 2020 Status changed to completed.
- 02 Jun 2011 New trial record